Foundation19
Posted - 2 hours ago
$AUTL very interesting chart direct from NASDAQ after hours quote. As I said earlier there were 400k shares traded after hours (unusual). but without the final 2.26 5 shares trade we would have ended at 2.33! do your own research!
humbled79
Posted - 6 hours ago
$AUTL I just looked at the website *Aucatzyl.com* and I notice that my hometown (Omaha) is one of the cities offering this treatment… this makes me want to contact the providers and get some more 1st-hand information…like are they already administering treatment? How well is this working for patients? Obviously they can’t divulge any personal information but I’m wondering if they can answer some general questions…What do you guys think?
Night_Owl_Biotech
Posted - 9 hours ago
Valuation related data points for all 15 comm'l-stage oncology focused bios w/market caps between $350MM & $7.5B as of Fri 12/20/24 (incl % change in SP from last Fri & shareholder profile) $GERN was down 10% & now trades a 1.8X analyst FY28 revenue estimates. This is the bottom quintile of this peer group with $IOVA & $SWTX. We've read GERN is confident in a $1.2B/year peak sale profile with the current label (add $1.8B if FY26's data read looks good). $DCTH also trades at a low multiple To us it appears $AUTL 's "debt" is a royalty obligation & not traditional term debt. If we're reading this right, & do your own research because we could be wrong, then AUTL trades for less than cash. However, AUTL (like BGNE & ADAP) may be subject to new US tariffs. All comm'l-stage bios may, again may, also be required to report global ASPs in the future (lowering reimbursements assuming ex-US pricing is lower than US). This is not investment advice. Do your own research
Foundation19
Posted - 1 day ago
$AUTL major buying blocks end of day. 800000 shares right the end and another 400000 post market. they were major buyers (not sell down) in my opinion.
PickemLowSellHigh
Posted - 1 day ago
$AUTL This sell off in AUTL is complete bullshit and manipulation of the highest order. Just wrap your head around this fact and tell me that getting this approved is not a big deal. I'm still in disbelief the stock is trading at cash: The FDA's Center for Drug Evaluation and Research (CDER) approves an average of about 46 novel drugs per year, including cancer drugs. In 2023, CDER approved 25 new oncology therapeutics, including drugs for lung, breast, and genitourinary cancers, as well as lymphoma and leukemia.
PickemLowSellHigh
Posted - 1 day ago
$AUTL 700k block trade at end of day. yeah, this is definitely some Scam St. special edition stuff. These fuckers know they can do whatever they want until next ER so they are basically selling this down to get every last share.
PickemLowSellHigh
Posted - 1 day ago
$AUTL I'm no expert on biotech stock price action after FDA approval but I doubt a 50% cut in sp is the norm. trading at $7.50 with no FDA and then $2.20 after FDA which is basically cash value is some dirty Scam St. magic trick.
Night_Owl_Biotech
Posted - 1 day ago
Yesterday Aadi Biosciences announced, among other things, a sale of its Fyarro therapy for certain ultra-rara cancers approved back in Nov. 2021. AADI opted to sell Fyarro after a clinical trial that would have dramatically expanded its label failed last summer Fyarro sales got to anticipated peak sales of $25MM/year, based on its initial label, within 5 - 6 quarters of launch. AADI sold Fyarro for $100MM creating a new peer valuation related data point for peer smaller cap comm'l-stage oncology focused bios of 4.0X ($100MM acquisition for $25MM in annual sales @ peak). Fyarro generated 89% gross margins & is patented thru Oct. 2040 This is not investment advice & certainly does not create "apples to apples" valuation expectations for AADI's larger cap peers but does suggest pot'l upside for comm'l-stage oncology focused peers like $ADAP $CKPT $DCTH $REPL & $AUTL if, and yes it is a huge if, these peers meet future revenue expectations
humbled79
Posted - 2 days ago
$AUTL Does anyone know specifically when the first 30 or so treatment centers will be actually treating patients? Monitoring the company’s execution strategy will be *top priority* Plans to open the additional 30 treatment centers tells me they are going full on adoption/market penetration!! And God willing, lots and lots of saved lives!!
humbled79
Posted - 2 days ago
$AUTL Just a reminder for those of us in the house of pain here…. There are 7 analysts covering AUTL. 0 say sell. 0 say hold. 7 say buy!! Average target price between the 7 analysts comes in at $10.32/share….representing a 361% upside from where we are right now. I may not be the smartest guy in the room, but the collective research done by these so-called experts lets me sleep comfortably at night. Don’t lose focus here…
Trickster86
Posted - 2 days ago
@StockAuthority what do you think about $AUTL
gandolf63
Posted - 2 days ago
$AUTL averaging down is like trying to catch a falling knife
Chachi88
Posted - 2 days ago
$AUTL Have a ton (at a large loss) in IRA, not worried, this will turn around in 2025 when revenue starts to flow. Buying more now when I can. NIA.
rubraquercus
Posted - 2 days ago
$AUTL almost cut in half since approval, this is a no brainer...<<Obe-cel's compelling safety profile over Tecartus and potentially better efficacy should make it the leading CAR-T therapy in adult ALL....The analyst increased Obe-cel market penetration to 60%, reflecting that it will be the dominant CAR-T in adult ALL. The analyst forecasts peak sales of $300 million.>>
Ixnay84
Posted - 2 days ago
$AUTL just added 1k more... bios are just beeing smashed...
LinguiniMatrimony
Posted - 2 days ago
$AUTL
Jabed206
Posted - 3 days ago
$AUTL pretty ugly path its on..
TheBiotechInvestor_
Posted - 3 days ago
$AUTL Great price to add, or enter if you are new here…
Here some DD for you.
https://youtu.be/Y18YqeNwFvs?si=lj44DkcM-Jjsg5pm
Joe_90_
Posted - 3 days ago
$AUTL any update from the company?
break82
Posted - 3 days ago
$AUTL we didn't forget anything
gandolf63
Posted - 3 days ago
$AUTL broke the $2.33 resistence heading to $1.80 it looks like
Stonkey
Posted - 3 days ago
$AUTL The bio sector is still a nightmare to invest in.....
gandolf63
Posted - 3 days ago
$AUTL How does a company with $700 million in cash and a deal with a major pharma player and new FDA appoval cancer drug sell off every day heading tona 5 year low?
huskyd97
Posted - 3 days ago
$AUTL dead money. I'll check back in 2025!
RFL2
Posted - 3 days ago
$AUTL I found something that might explain the decline of the stock. While several of the adverse effects are less than other car t therapies The incidence of grade 3 infection is 41%, much higher than the infection rate of bincyto, which I remember to be 15%. I do realize bincyto is not a car t but it is a competitive therapy for the same indication.
Trending__Now
Posted - 3 days ago
$AUTL Capital has exited the stock market and share price suffers as a result. Less buyers. For the new investors or for those that forgot, the US 10-yr Treasury is a decent guide. Above 4%, not good, below 4% good. Simple. The other guide would be influx of capital in January that typically pushes the market higher. Eventually, institutional investors look for companies undervalued. Earnings will begin to appear 2Q maybe 1Q, that'd be nice. That gets investors attention. We're trading at cash value. Ignore the stupid that are shorting a company trading at cash value. You've been given a gift at this price. Buy, hold and wait. 12 months from now the share price will be a very different story. Crystal ball sez 3X minimum.
LinguiniMatrimony
Posted - 3 days ago
$AUTL
PickemLowSellHigh
Posted - 3 days ago
$AUTL when is AUTL going to be added to the XBI? so many shit stock there I'm surprised AUTL hasn't been added.
PhoenixFondel
Posted - 3 days ago
$AUTL I’ll add more in the high $1’s.